Emerging biological treatments in inflammatory bowel diseases

Digestive Diseases

Volumn 24, Issue 1-2, 2006, Pages 131-136

  Van Assche, Gert ^a   Vermeire, Séverine ^a   Rutgeerts, Paul ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Biological treatment; Controlled trials; Crohn's disease; Inflammatory bowel diseases; Medical treatment; Ulcerative colitis

Indexed keywords

ABT 874; ADALIMUMAB; ALICAFORSEN; BASILIXIMAB; CALCINEURIN INHIBITOR; CERTOLIZUMAB PEGOL; CYCLOSPORIN; DACLIZUMAB; FONTOLIZUMAB; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 6 RECEPTOR ANTIBODY; ISIS 2303; MLN 02; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD3; MONOCLONAL ANTIBODY MRA; NATALIZUMAB; PROTEIN INHIBITOR; RECEPTOR ANTIBODY; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; SELECTIVE ADHESION MOLECULE INHIBITING AGENT; STEROID; TACROLIMUS; TYSABRIM; UNCLASSIFIED DRUG; VISILIZUMAB;

ANTIBODY PRODUCTION; BIOLOGICAL THERAPY; BONE PAIN; BRAIN INFECTION; CLINICAL TRIAL; COLON RESECTION; CROHN DISEASE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOXICITY; DRUG TREATMENT FAILURE; ENTERITIS; FEEDBACK SYSTEM; GRAFT REJECTION; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; T LYMPHOCYTE; ULCERATIVE COLITIS;

ANTIBODIES, MONOCLONAL; BIOLOGICAL THERAPY; CONTROLLED CLINICAL TRIALS; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATORY BOWEL DISEASES; TREATMENT OUTCOME;

EID: 33646732428     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000090316     Document Type: Review

References (31)

1. Baert F, Noman M, Vermeire S, Van Assche G, D'Haens G, Carbonez A, Rutgeerts P: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-608.
2. Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P: Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003; 124:917-924.
3. Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Hanauer SB: Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004;126:402-413.
4. Probert CS, Hearing SD, Schreiber S, Kuhbacher T, Ghosh S, Arnott ID, Forbes A: Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003;52:998-1002.
5. Jarnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlen P, Granno C, Vilien M, Strom M, Danielsson A, Verbaan H, Hellstrom PM, Magnuson A, Curman B: Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005;128:1805-1811.
6. Sandborn WJ, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Olson A, Johanns J, Travers S, Colombel JF: Infliximab induction and maintenance therapy for ulcerative colitis: the Act-2 trial. Gastroenterology 2005;128:A104.
7. Rutgeerts P, Feagan BG, Olson A, Johanns J, Travers S, Present D, Sands BE, Sandborn WJ, Olson A: A randomized placebo-controlled trial of infliximab therapy for active ulcerative colitis: Act 1 trial. Gastroenterology 2005;128: A105.
8. Youdim A, Vasiliauskas EA, Targan SR, Papadakis KA, Ippoliti A, Dubinsky MC, Lechago J, Paavola J, Loane J, Lee SK, Gaiennie J, Smith K, Do J, Abreu MT: A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis 2004;10:333-338.
9. Sandborn WJ, Hanauer S, Loftus EV Jr, Tremaine WJ, Kane S, Cohen R, Hanson K, Johnson T, Schmitt D, Jeche R: An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 2004;99:1984-1989.
10. Hanauer S, Lukáš M, MacIntosh D, Rutgeerts P, Sandborn W, Pollack P: A randomized, double-blind, placebo-controlled trial of the human anti-TNF-α monoclonal antibody adalimumab for the induction of remission in patients with moderate to severely active Crohn's disease. Gastroenterology 2004;126: A332 (abstract).
11. Shen C, Assche GV, Colpaert S, Maerten P, Geboes K, Rutgeerts P, Ceuppens JL: Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther 2005;21:251-258.
12. Schreiber S, Fedorak R, Rutgeerts P, Innes A, Patel J: CDP870, a pegylated humanized anti-TNF antibody fragment offers particular benefit to Crohn's disease patients with elevated c-reactive protein. Gut 2003;52(suppl):A4.
13. Miller DH, Khan OA, Sheremata WA, et al: A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003;348:15-23.
14. Ghosh S, Goldin E, Gordon FH, et al: Natalizumab for active Crohn's disease. N Engl J Med 2003;348:24-32.
15. Rutgeerts P, Enns R, Colombel JF, et al: 6-month steroid sparing results of natalizumab in a controlled study of patients with Crohn's disease. Gut 2004;53:A48.
16. Sandborn W, Colombel JF, Enns R, Feagan B, Hanauer S, Lawrance I, Panaccione R, Sanders M, Schreiber S, Targan SR, van Deventer SJ, Rutgeerts P: A phase III, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of antegren (Natalizumab) in maintaining clinical response and remission in Crohn's disease (ENACT-2). Gastroenterology 2004;127:332.
17. Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman M, Verbeeck J, Geboes K, Robberecht W, Rutgeerts P: Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005;353:362-368. Epub 2005 Jun 9.
18. Kleinschmidt-Demasters BK, Tyler KL: Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005;353:369-374. Epub 2005 Jun 9.
19. Langer-Gould A, Atlas SW, Bollen AW, Pelletier D: Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353:375-381. Epub 2005 Jun 9.
20. Feagan BG, Greenberg GR, Wild G, Fedorak RN, Pare P, McDonald JW, Dube R, Cohen A, Steinhart AH, Landau S, Aguzzi RA, Fox IH, Vandervoort MK: Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005;352: 2499-2507.
21. Van Deventer SJ, Tami JA, Wedel MK, et al: An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1 in active ulcerative colitis. Gut 2004;53: 1646-1651.
22. Miner P, Wedel M, Bane B, Bradely J, et al: An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in chronic intermitting pouchitis. Aliment Pharmacol Ther 2004;19:281-286.
23. Mannon P, Fuss I, Mayer L, Elson CO, Sandborn WJ, Dolin B, Goodman N, Groden C, Hornung R, Salfeld J, Veldman GM, Schwertschlag U, Strober W, Group ftI-iCsDS: Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004;352: 2069-2079.
24. Hommes D, Mikhajlova T, Stoinov S, Stimac D, Vucelic B, Lonovics J, Zakuciova M, D'haens G, Van Assche G, Pearce T: Fontolizumab (Huzaf), a humanized anti-IFN-gamma antibody, has clinical activity and excellent tolerability in moderate to severe Crohn's disease. Gastroenterology 2004;127:332.
25. Creed TJ, Norman MR, Probert CS, Harvey RF, Shaw IS, Smithson J, Anderson J, Moorghen M, Gupta J, Shepherd NA, Dayan CM, Hearing SD: Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment Pharmacol Ther 2003;18:65-75.
26. Van Assche G, Dalle I, Noman M, et al: A pilot study on the use of the humanized anti interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am J Gastroenterol 2003;98:369-376.
27. Protein Design Labs reports negative results in phase II clinical trial with daclizumab in ulcerative colitis: PDL Press release, May 2004. Available at: http://www.pdl.com
28. Ito H, Takazoe M, Fukuda Y, Hibi T, Kusugami K, Andoh A, Matsumoto T, Yamamura T, Azuma J, Nishimoto N, Yoshizaki K, Shimoyama T, Kishimoto T: A pilot randomized trial of a human anti-interleukin-6 monoclonal antibody in active Crohn's disease. Gastroenterology 2004;126:989-996.
29. Korzenik JR, Dieckgraefe BK, Valentine JF: Duration of sagramostim effect in patients with moderately-to-severely active Crohn's disease: follow up results from a randomized, double blind, placebo controlled trial (abstract). Gastroenterology 2004;126:A475.
30. Arts J, D'Haens G, Zeegers M, Van Assche G, Hiele M, D'Hoore A, Penninckx F, Vermeire S, Rutgeerts P: Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis 2004;10:73-78.
31. Plevy S, Salzberg B, Hommes D, Van Assche G, Regueiro M, Sandborn W, Hanauer S, Targan S, Mayer L, Mahadevan U, Lowder J: A humanized anti-CD3 monoclonal antibody, visilizumab, for the treatment of severe steroid-refractory ulcerative colitis: results of a phase I study (abstract). Gastroenterology 2004;126:A75.